A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of Aldafermin Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study closed

(956) 362-8047

Please contact us for more information or to learn if you are eligible to participate.

The primary objectives are to evaluate the efficacy, safety, and tolerability of aldafermin based on liver histology at 24 weeks versus placebo

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390